



# 59th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE 2021 Online)

Online, September 22–26, 2021

## Abstracts

Guest Editor

*Mehul Dattani, London, UK*

Programme Organising Committee

Nils Krone, Sheffield, UK, *Chair*

Mehul Dattani, London, UK, *President 2021*

Poonam Dharmaraj, Liverpool, UK, *Vice President 2021*

Stefano Cianfarini, Rome, Italy, *President-Elect*

Evangelia Charmandari, Athens, Greece, *Chair of Clinical Practice Committee*

Ola Nilsson, Örebro, Sweden, *Member*

Philippe Lysy, Brussels, Belgium, *Member*

Malgorzata Wasniewska, Messina, Italy, *Member*

---

## Disclosure Statement Guest Editor

The guest editor does not have any conflicts of interest to declare.

## This publication was sponsored by

Merck  
Novo Nordisk  
Pfizer  
Sandoz

S. Karger  
Medical and Scientific Publishers  
Basel • Freiburg • Hartford • Oxford •  
Bangkok • Dubai • Kuala Lumpur •  
Melbourne • Mexico City • Moscow •  
New Delhi • Paris • Shanghai • Tokyo

### Disclaimer

The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

### Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

### All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 2021 by S. Karger AG,  
P.O. Box, CH-4009 Basel (Switzerland)  
e-ISBN 978-3-318-07016-3

# Contents

## Plenary Lectures

|   |     |   |   |
|---|-----|---|---|
| 1 | PL1 | A Kiss before Sex   | 1 |
| 1 | PL2 | New Drugs for Youth with Type 2 Diabetes                                | 2 |
| 2 | PL3 | Iodine Deficiency: A Public Health Issue                                | 3 |
| 2 | PL4 | Development of Novel Therapies for Obesity                              | 4 |
| 2 | PL5 | Advances and Challenges in the Care of Transgender/Gender Diverse Youth | 5 |
| 2 | PL6 | The Current State of Epigenetic Research in Humans: Promise and Reality | 6 |
| 2 | PL7 | Novel Insights into Weight Regulation                                   | 7 |
| 2 | PL8 | The Long Term Effects of Adolescent Obesity                             | 8 |

## Symposia

|   |     |  |           |
|---|-----|--|-----------|
| 3 | S1  | Endocrine Hypertension – Aetiology Directed Management                           | 1.1–1.2   |
| 4 | S2  | Recent Breakthroughs in our Understanding of Calcium and Phosphate Homeostasis   | 2.1–2.2   |
| 4 | S3  | Management of Rare Obesity   | 3.1–3.2   |
| 5 | S4  | Recent Developments in Congenital Adrenal Hyperplasia                            | 4.1–4.2   |
| 5 | S5  | Novel Therapies in Endocrinology   | 5.1–5.2   |
| 6 | S6  | Bone Formation: The Growth Plate and Beyond                                      | 6.1–6.2   |
| 6 | S7  | The Molecular Basis of Rare Endocrine Disorders                                  | 7.1–7.2   |
| 6 | S8  | Management of Childhood Brain Tumours  | 8.1–8.2   |
| 7 | S9  | Surgical Management of Endocrine Disorders                                       | 9.1–9.2   |
| 7 | S10 | Pathways to Improved Diagnosis and Management of Hypothalamo-Pituitary Disorders | 10.1–10.2 |
| 8 | S11 | Calcium and Phosphate Beyond Bone  | 11.1–11.2 |
| 8 | S12 | Epigenetics and Genetics in Endocrine Disorders                                  | 12.1–12.2 |
| 9 | S13 | Joint ESPE/ISPAD Symposium: Novel Technologies in the Treatment of Diabetes      | 13.1–13.2 |

## Meet the Expert

|    |      |   |   |
|----|------|---|---|
| 10 | MTE1 | Thyroid Hormone Resistance Syndromes                        | 1 |
| 10 | MTE2 | Diagnosis and Management of a Child with Pituitary Adenoma  | 2 |
| 10 | MTE3 | Management of a Child with Post-Neurosurgical Hyponatraemia | 3 |
| 10 | MTE4 | Cystic Fibrosis-Related Diabetes                            | 4 |
| 10 | MTE5 | Management of MEN1 in Children and Adolescents              | 5 |
| 10 | MTE6 | Autoimmune Endocrinopathy                                   | 6 |
| 11 | MTE7 | Endocrine and Osteoporosis Management of Boys with DMD      | 7 |
| 11 | MTE8 | Real-Life Diabetes Management during Exercise               | 8 |

## How Do I...

|    |      |                       |         |
|----|------|-----------------------|---------|
| 11 | HDI1 | How Do I... Session 1 | 1.1–1.3 |
| 11 | HDI2 | How Do I... Session 2 | 2.1–2.3 |

|    |                                       |   |             |
|----|---------------------------------------|---|-------------|
|    | <b>Controversies</b>                  |   |             |
| 12 | CON1                                  | Should CGM be Used in Every Child with Diabetes?  | 1.1–1.2     |
| 12 | CON2                                  | Should Children with Isolated Idiopathic GHD be Retested in Early/Mid-Puberty, rather than Wait until Adult Height is Achieved? | 2.1–2.2     |
|    | <b>GPED</b>                           |   |             |
| 13 | GPED                                  | The Use of Long-Acting Insulin Analogues in Low and Middle Income Countries   | 1.1–1.2     |
|    | <b>Young Investigators</b>            |   |             |
| 14 | YI                                    | Young Investigators   | 1.1–1.5     |
|    | <b>Working Group Symposia</b>         |   |             |
| 15 | WG1                                   | ESPE Working Group on Bone and Growth Plate (BGP) Symposium   | 1.1–1.3     |
| 16 | WG2                                   | ESPE Working Group on Obesity (OWG) Symposium   | 2.1–2.2     |
| 16 | WG3                                   | ESPE Working Group on Diabetes Technology (DT) Symposium  | 3.1–3.3     |
| 17 | WG4                                   | ESPE Working Group on Disorders of Sex Development (DSD) Symposium  | 4.1–4.2     |
| 18 | WG5                                   | ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG) Symposium   | 5.1–5.2     |
| 18 | WG6                                   | ESPE Working Group on Gender Incongruence (GI) Symposium  | 6.1–6.2     |
| 19 | WG7                                   | ESPE Working Group for Paediatric Endocrine Nurses (ESPEN) Symposium  | 7.1–7.3     |
| 19 | WG8                                   | ESPE Working Group on Turner Syndrome Symposium   | 8.1–8.3     |
|    | <b>Endo-ERN Symposium</b>             |   |             |
| 20 | EE                                    | Endo-ERN Symposium  | 1.1–1.3     |
|    | <b>ESPE Yearbook Sessions</b>         |   |             |
| 21 | YB1                                   | Year of Paediatric Endocrinology 1  | 1.1–1.5     |
| 22 | YB2                                   | Year of Paediatric Endocrinology 2  | 2.1–2.5     |
| 23 | YB3                                   | Year of Paediatric Endocrinology 3  | 3.1–3.5     |
|    | <b>Henning Andersen Prize Winners</b> |   |             |
| 24 | HA1                                   | A Global Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Outcomes in Participants Aged <25 Years | 1           |
| 24 | HA2                                   | Biphasic Pattern of Circulating Reproductive Hormones in Female Infants – The Longitudinal COPENHAGEN Minipuberty Study         | 2           |
|    | <b>Free Communications</b>            |   |             |
| 25 | FC1                                   | Adrenal   | 1.1–1.6     |
| 30 | FC2                                   | Fat Metabolism and Obesity  | 2.1–2.6     |
| 33 | FC3                                   | Growth Disorders  | 3.1–3.6     |
| 36 | FC4                                   | Diabetes  | 4.1–4.6     |
| 40 | FC5                                   | Sex Development and Gender Incongruence   | 5.1–5.6     |
| 43 | FC6                                   | Bone and Mineral Metabolism   | 6.1–6.6     |
| 48 | FC7                                   | Fetal Endocrinology and Multisystem Disorders   | 7.1–7.6     |
| 52 | FC8                                   | Neuroendocrinology  | 8.1–8.6     |
| 56 | FC9                                   | Growth Hormone and IGFs   | 9.1–9.6     |
| 59 | FC10                                  | Thyroid   | 10.1–10.6   |
|    | <b>ePoster Presentations</b>          |   |             |
|    | <b>ePoster Category 1</b>             |   |             |
| 63 | P1                                    | Adrenal A   | P1-1–P1-10  |
| 71 | P1                                    | Bone A  | P1-11–P1-20 |
| 76 | P1                                    | Diabetes A  | P1-21–P1-30 |
| 81 | P1                                    | Fat, Metabolism and Obesity A   | P1-31–P1-40 |

|                           |                     |   |               |
|---------------------------|---------------------|---|---------------|
| 86                        | P1                  | Sex Endocrinology and Gonads A  | P1-41–P1-50   |
| 93                        | P1                  | Bone B  | P1-51–P1-60   |
| 98                        | P1                  | Diabetes B  | P1-61–P1-70   |
| 103                       | P1                  | Fetal Endocrinology and Multisystem Disorders A                         | P1-71–P1-80   |
| 108                       | P1                  | Pituitary A   | P1-81–P1-90   |
| 114                       | P1                  | Thyroid A   | P1-91–P1-100  |
| 120                       | P1                  | Adrenal B   | P1-101–P1-110 |
| 125                       | P1                  | Fat, Metabolism and Obesity B   | P1-111–P1-120 |
| 131                       | P1                  | Growth A  | P1-121–P1-130 |
| 137                       | P1                  | Growth Hormone and IGFs A   | P1-131–P1-140 |
| 143                       | P1                  | Sex Endocrinology and Gonads B  | P1-141–P1-150 |
| 150                       | P1                  | Fetal Endocrinology and Multisystem Disorders B                         | P1-151–P1-160 |
| 155                       | P1                  | Growth B  | P1-161–P1-170 |
| 161                       | P1                  | Growth Hormone and IGFs B   | P1-171–P1-180 |
| 167                       | P1                  | Pituitary B   | P1-181–P1-190 |
| 172                       | P1                  | Thyroid B   | P1-191–P1-200 |
| <b>ePoster Category 2</b> |                     |   |               |
| 177                       | P2                  | Adrenals and HPA Axis   | P2-1–P2-57    |
| 207                       | P2                  | Bone, Growth Plate and Mineral Metabolism                               | P2-58–P2-98   |
| 226                       | P2                  | Diabetes and Insulin  | P2-99–P2-170  |
| 261                       | P2                  | Fat Metabolism and Obesity  | P2-171–P2-229 |
| 292                       | P2                  | Fetal, Neonatal Endocrinology and Metabolism (to Include Hypoglycaemia) | P2-230–P2-245 |
| 300                       | P2                  | Growth Hormone and IGFs   | P2-246–P2-276 |
| 317                       | P2                  | Growth and Syndromes (to Include Turner Syndrome)                       | P2-277–P2-332 |
| 346                       | P2                  | Multisystem Endocrine Disorders   | P2-333–P2-345 |
| 351                       | P2                  | Pituitary, Neuroendocrinology and Puberty                               | P2-346–P2-393 |
| 375                       | P2                  | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology        | P2-394–P2-445 |
| 400                       | P2                  | Thyroid   | P2-446–P2-491 |
| 424                       | <b>Author Index</b> |   |               |